Surface Oncology (Surface Oncology) Revenue per Share : $0.00 (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology Revenue per Share?

Surface Oncology's revenue per share for the three months ended in Jun. 2023 was $0.00. Surface Oncology's revenue per share for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

Warning Sign:

Surface Oncology Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Surface Oncology was -100.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -0.80% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -26.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Surface Oncology's Revenue per Share or its related term are showing as below:

SURF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -72.6 Med: 8.15 Max: 70.9
Current: -0.8

During the past 7 years, Surface Oncology's highest 3-Year average Revenue Per Share Growth Rate was 70.90% per year. The lowest was -72.60% per year. And the median was 8.15% per year.

SURF's 3-Year Revenue Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.4 vs SURF: -0.80

Surface Oncology Revenue per Share Historical Data

The historical data trend for Surface Oncology's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology Revenue per Share Chart

Surface Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Revenue per Share

Get a 7-Day Free Trial

2.97

0.55

3.31

0.06

0.54

Surface Oncology Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Revenue per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Surface Oncology's Revenue per Share

For the Biotechnology subindustry, Surface Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Surface Oncology's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Surface Oncology's PS Ratio distribution charts can be found below:

* The bar in red indicates where Surface Oncology's PS Ratio falls into.

Surface Oncology Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Surface Oncology's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Revenue Per Share (A: Dec. 2022 )	=	Revenue (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	30	/	55.761
	=	0.54

Surface Oncology's Revenue Per Share for the quarter that ended in Jun. 2023 is calculated as

Revenue Per Share (Q: Jun. 2023 )	=	Revenue (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	0	/	60.718
	=	0.00

Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Surface Oncology (NAS:SURF) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Surface Oncology Revenue per Share Related Terms

Thank you for viewing the detailed overview of Surface Oncology's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Surface Oncology (Surface Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139

Website

https://www.surfaceoncology.com

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.

Executives

Chandra Adams	officer: Deputy GC	SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill	officer: Chief Medical Officer
Jessica Fees	officer: See Remarks	C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross	officer: Chief Medical Officer	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath	officer: Chief Business Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella	officer: Chief Scientific Officer	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn	director	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey	director	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater	director, officer: Chief Executive Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p.	10 percent owner	46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc	10 percent owner	56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118